

Tepotinib (TEPMETKO) Criteria for Use December 2021

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at www.pbm.va.gov or [PBM INTRAnet](#) for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive Tepotinib.

- CrCl <30 mL/min
- Prior treatment with another MET inhibitor
- Moderate or Severe Hepatic Insufficiency: AST/ALT > 3 × ULN or total bilirubin > 1.5 × ULN. For patients with liver metastases: AST/ALT > 5 × ULN or total bilirubin > 1.5 × ULN.
- Inadequate hematologic function with one of the following: Hgb <8.5 g/dL or Neutrophils <1.5 × 10⁹/L or Plt <100 × 10⁹/L
- Presence of ALK mutation or sensitive EGFR mutation (exon 19 del or exon 21 alteration)
- NYHA heart failure Class III or IV
- Untreated brain metastases
- Pregnancy (i.e. known pregnancy or positive pregnancy test)
- Breastfeeding

Inclusion Criteria

The answers to ALL of the following must be fulfilled in order to meet criteria.

- Care is provided by a VA/VA Community Care oncology provider
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Goals of care and role of Palliative Care consult have been discussed and documented
- Patients of child-bearing potential and patients with partners of child-bearing potential: counseling provided on contraception and risks vs. benefits of treatment. Use effective contraception during therapy and for one week after the last dose.

Additional Inclusion Criteria

The answer to the following must be fulfilled in order to meet criteria:

- Patients with metastatic non-small cell lung cancer with a MET exon 14 skipping mutation

Prepared: November 2021. Contact: Mark C. Geraci, Pharm.D., BCOP, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services 10P4P
